Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

NCT06440850 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
21
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

City of Hope Medical Center

Collaborators